Graham Capital Management L.P. Raises Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Graham Capital Management L.P. raised its position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 32.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 70,662 shares of the company’s stock after purchasing an additional 17,209 shares during the period. Graham Capital Management L.P.’s holdings in Xeris Biopharma were worth $240,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. NewEdge Advisors LLC acquired a new position in shares of Xeris Biopharma in the fourth quarter valued at approximately $34,000. R Squared Ltd acquired a new position in Xeris Biopharma during the fourth quarter worth $42,000. Cibc World Markets Corp acquired a new position in Xeris Biopharma during the fourth quarter worth $44,000. Raymond James Financial Inc. acquired a new position in Xeris Biopharma during the fourth quarter worth $45,000. Finally, Aquatic Capital Management LLC acquired a new position in Xeris Biopharma during the fourth quarter worth $50,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Insider Transactions at Xeris Biopharma

In related news, insider Beth Hecht sold 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total value of $217,200.00. Following the sale, the insider now owns 1,353,510 shares of the company’s stock, valued at approximately $7,349,559.30. This trade represents a 2.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 6.47% of the company’s stock.

Xeris Biopharma Stock Performance

XERS stock opened at $4.88 on Monday. The firm has a market cap of $763.16 million, a P/E ratio of -10.84 and a beta of 1.10. Xeris Biopharma Holdings, Inc. has a 1 year low of $1.86 and a 1 year high of $6.07. The stock has a 50-day simple moving average of $4.72 and a 200-day simple moving average of $3.91.

Xeris Biopharma (NASDAQ:XERS) last announced its earnings results on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.01. The company had revenue of $57.80 million for the quarter, compared to analysts’ expectations of $57.61 million. On average, equities research analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

Analyst Ratings Changes

Several analysts have weighed in on XERS shares. Craig Hallum upped their target price on Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a report on Friday, March 7th. HC Wainwright reiterated a “buy” rating and set a $8.00 target price (up from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. Leerink Partners increased their target price on Xeris Biopharma from $5.00 to $6.00 and gave the stock an “outperform” rating in a research report on Friday, March 7th. Jefferies Financial Group reiterated a “buy” rating and set a $6.00 target price (up from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. Finally, Piper Sandler reiterated a “neutral” rating and set a $4.00 target price (up from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $6.25.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.